238.74
+6.39%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Glaukos
From its filings with the US Securities and Exchange Commission
Glaukos is based in Aliso Viejo, California and is incorporated in Delaware. Its shares trade on NYSE under the ticker GKOS. The SEC classifies its business as surgical & medical instruments & apparatus. In the fiscal year to 31 December 2025, it reported revenue of $507.4m and a net loss of $187.7m. At that date it held total assets of $893.5m and shareholders' equity of $656.2m.
Glaukos is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal disease. We first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching our first MIGS device, the iStent, commercially in 2012. In 2024, we commenced commercialization activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. We also offer commercially proprietary bio-activated pharmaceutical therapies for the treatment of corneal disorders. Beyond our approved products, we continue to develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.
Ophthalmic diseases and disorders are a national and global health concern and, as the population ages, the number of individuals with vision impairment and blindness is increasing. Moreover, improving access to cost-effective tools is increasing the diagnosis of sight-threatening ocular diseases globally and driving demand for innovative products, technologies, and therapies that improve clinical outcomes, demonstrate favorable safety profiles and provide ease of use and reliability.
Quoted from its 10-K, filed 23 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 25 Jun 2015
- Employees
- 1,094
- Website
- glaukos.com ↗
- Head office
- 1 GLAUKOS WAY, ALISO VIEJO, CA, 92656
- Incorporated in
- DE
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Thomas BurnsChairman of the Board, Chief Executive Officer, since 2002$9.0m
- Mr. Joseph GilliamPresident, Chief Operating Officer$4.2m
- Mr. Alex ThurmanChief Financial Officer, Senior Vice President$2.5m
- Dr. Tomas NavratilChief Development Officer$2.8m
- Mr. Mark FoleyLead Independent Director$377,470
- Mr. David HoffmeisterIndependent Director$348,371
- Dr. Gilbert KlimanIndependent Director, since 2020$333,957
- Mr. Marc StapleyIndependent Director$345,442
- Ms. Denice TorresIndependent Director$333,957
- Ms. Aimee WeisnerIndependent Director$333,957
- Dr. Leana WenIndependent Director$324,970
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 63
- Environment
- 33
- Social
- 99
- Governance
- 57
- Direct emissions (scope 1)
- 575.4 t
- Energy emissions (scope 2)
- 2,159.4 t
- Women in the workforce
- 40%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Glaukos Corp possesses several key strengths that contribute to its success in the market:
Weaknesses
- While Glaukos Corp has several strengths, there are also some weaknesses that need to be addressed for sustainable growth:
Opportunities
- Glaukos Corp can leverage the following opportunities to further enhance its position in the market:
Threats
- Glaukos Corp faces certain threats that could impact its performance and market position:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.